{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:11:04Z","timestamp":1790359864570,"version":"4.1.0"},"publisher-location":"Cham","reference-count":112,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030556167","type":"print"},{"value":"9783030556174","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-55617-4_3","type":"book-chapter","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T03:39:08Z","timestamp":1612928348000},"page":"51-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer"],"prefix":"10.1007","author":[{"given":"Ramesh B.","family":"Batchu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana V.","family":"Gruzdyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala K.","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Dachepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem S.","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan S.","family":"Tavva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"issue":"1","key":"3_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"3_CR2","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/IGC.0000000000001328","volume":"28","author":"A Babayeva","year":"2018","unstructured":"Babayeva A, Braicu EI, Grabowski JP et al (2018) Clinical outcome after completion surgery in patients with ovarian cancer: the Charite experience. Int J Gynecol Cancer 28(8):1491\u20131497","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"3_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10585-014-9658-1","volume":"31","author":"L Carduner","year":"2014","unstructured":"Carduner L, Leroy-Dudal J, Picot CR, Gallet O, Carreiras F, Kellouche S (2014) Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependent on alphav integrins. Clin Exp Metastasis 31(6):675\u2013688","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"3_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ejca.2006.01.013","volume":"42","author":"L Yan","year":"2006","unstructured":"Yan L, Anderson GM, DeWitte M, Nakada MT (2006) Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 42(6):793\u2013802","journal-title":"Eur J Cancer"},{"issue":"2","key":"3_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2011.02496.x","volume":"271","author":"C Trumpfheller","year":"2012","unstructured":"Trumpfheller C, Longhi MP, Caskey M et al (2012) Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 271(2):183\u2013192","journal-title":"J Intern Med"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1\u201322","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"3_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/sj.cdd.4402235","volume":"15","author":"CW Chan","year":"2008","unstructured":"Chan CW, Housseau F (2008) The \u2018kiss of death\u2019 by dendritic cells to cancer cells. Cell Death Differ 15(1):58\u201369","journal-title":"Cell Death Differ"},{"issue":"11","key":"3_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991\u2013998","journal-title":"Nat Immunol"},{"issue":"7","key":"3_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/intimm\/dxw020","volume":"28","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi J, Mandai M, Konishi I (2016) Immune checkpoint inhibition in ovarian cancer. Int Immunol 28(7):339\u2013348","journal-title":"Int Immunol"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.gore.2019.06.003","volume":"29","author":"DW Doo","year":"2019","unstructured":"Doo DW, Norian LA, Arend RC (2019) Checkpoint inhibitors in ovarian cancer: a review of preclinical data. Gynecol Oncol Rep 29:48\u201354","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"3_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.intimp.2018.12.051","volume":"68","author":"L Li","year":"2019","unstructured":"Li L, Ma Y, Xu Y (2019) Follicular regulatory T cells infiltrated the ovarian carcinoma and resulted in CD8 T cell dysfunction dependent on IL-10 pathway. Int Immunopharmacol 68:81\u201387","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2796.2010.02235.x","volume":"268","author":"L Norling","year":"2010","unstructured":"Norling L, Serhan C (2010) Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med 268(1):15\u201324","journal-title":"J Intern Med"},{"issue":"3","key":"3_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","volume":"21","author":"JA Magee","year":"2012","unstructured":"Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21(3):283\u2013296","journal-title":"Cancer Cell"},{"issue":"10","key":"3_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014\u20131022","journal-title":"Nat Immunol"},{"issue":"2","key":"3_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3892\/ijmm.2015.2230","volume":"36","author":"X Deng","year":"2015","unstructured":"Deng X, Zhang P, Liang T, Deng S, Chen X, Zhu L (2015) Ovarian cancer stem cells induce the M2 polarization of macrophages through the PPARgamma and NF-kappaB pathways. Int J Mol Med 36(2):449\u2013454","journal-title":"Int J Mol Med"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271","journal-title":"Annu Rev Immunol"},{"key":"3_CR18","doi-asserted-by":"crossref","unstructured":"House CD, Hernandez L, Annunziata CM (2015) In vitro enrichment of ovarian cancer tumor-initiating cells. J Vis Exp 96","DOI":"10.3791\/52446"},{"issue":"7","key":"3_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.tips.2016.04.006","volume":"37","author":"N Syn","year":"2016","unstructured":"Syn N, Wang L, Sethi G, Thiery JP, Goh BC (2016) Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci 37(7):606\u2013617","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"3_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1593\/neo.91824","volume":"12","author":"CJ Arum","year":"2010","unstructured":"Arum CJ, Anderssen E, Viset T et al (2010) Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer. Neoplasia 12(6):434\u2013442","journal-title":"Neoplasia"},{"issue":"5","key":"3_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","volume":"165","author":"W Wang","year":"2016","unstructured":"Wang W, Kryczek I, Dostal L et al (2016) Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165(5):1092\u20131105","journal-title":"Cell"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4137\/CMO.S38333","volume":"10","author":"MP Jammal","year":"2016","unstructured":"Jammal MP, Martins-Filho A, Silveira TP, Murta EF, Nomelini RS (2016) Cytokines and prognostic factors in epithelial ovarian cancer. Clin Med Insights Oncol 10:71\u201376","journal-title":"Clin Med Insights Oncol"},{"issue":"2","key":"3_CR23","first-page":"122","volume":"21","author":"A Rabinovich","year":"2010","unstructured":"Rabinovich A, Medina L, Piura B, Huleihel M (2010) Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21(2):122\u2013128","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"3_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.currproblcancer.2016.11.003","volume":"41","author":"V Krishnan","year":"2017","unstructured":"Krishnan V, Berek JS, Dorigo O (2017) Immunotherapy in ovarian cancer. Curr Probl Cancer 41(1):48\u201363","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"3_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13277-014-2848-2","volume":"36","author":"DH Wang","year":"2015","unstructured":"Wang DH, Guo L, Wu XH (2015) Checkpoint inhibitors in immunotherapy of ovarian cancer. Tumour Biol 36(1):33\u201339","journal-title":"Tumour Biol"},{"issue":"12","key":"3_CR26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2217\/imt.14.90","volume":"6","author":"CL Schwab","year":"2014","unstructured":"Schwab CL, English DP, Roque DM, Pasternak M, Santin AD (2014) Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 6(12):1279\u20131293","journal-title":"Immunotherapy"},{"issue":"32","key":"3_CR27","doi-asserted-by":"publisher","first-page":"22832","DOI":"10.18632\/oncotarget.25126","volume":"9","author":"A Ghoneum","year":"2018","unstructured":"Ghoneum A, Afify H, Salih Z, Kelly M, Said N (2018) Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget 9(32):22832\u201322849","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"3_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2007.03.011","volume":"186","author":"T Roy","year":"2007","unstructured":"Roy T, Paul S, Baral RN, Chattopadhyay U, Biswas R (2007) Tumor associated release of interleukin-10 alters the prolactin receptor and down-regulates prolactin responsiveness of immature cortical thymocytes. J Neuroimmunol 186(1\u20132):112\u2013120","journal-title":"J Neuroimmunol"},{"issue":"7","key":"3_CR29","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-07-0118","volume":"6","author":"T Hagemann","year":"2007","unstructured":"Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR (2007) Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 6(7):1993\u20132002","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00262-011-1128-x","volume":"61","author":"MJ Dobrzanski","year":"2012","unstructured":"Dobrzanski MJ, Rewers-Felkins KA, Samad KA et al (2012) Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate \u201cnatural\u201d and \u201cinducible\u201d CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 61(6):839\u2013854","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2008.10.019","volume":"45","author":"A Mustea","year":"2009","unstructured":"Mustea A, Braicu EI, Koensgen D et al (2009) Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine 45(1):8\u201311","journal-title":"Cytokine"},{"issue":"2","key":"3_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10875-009-9353-1","volume":"30","author":"X Zhu","year":"2010","unstructured":"Zhu X, Ma D, Zhang J et al (2010) Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol 30(2):253\u2013259","journal-title":"J Clin Immunol"},{"issue":"1","key":"3_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.0105-2896.2004.00199.x","volume":"202","author":"MJ Smyth","year":"2004","unstructured":"Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202(1):275\u2013293","journal-title":"Immunol Rev"},{"issue":"12","key":"3_CR34","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.ejca.2011.03.026","volume":"47","author":"R Yigit","year":"2011","unstructured":"Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF (2011) Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 47(12):1883\u20131889","journal-title":"Eur J Cancer"},{"issue":"3","key":"3_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ygyno.2004.08.024","volume":"95","author":"AW Bushley","year":"2004","unstructured":"Bushley AW, Ferrell R, McDuffie K et al (2004) Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 95(3):672\u2013679","journal-title":"Gynecol Oncol"},{"issue":"4960","key":"3_CR36","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1126\/science.2161559","volume":"248","author":"KW Moore","year":"1990","unstructured":"Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248(4960):1230\u20131234","journal-title":"Science"},{"issue":"2\u20133","key":"3_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12307-018-0215-3","volume":"11","author":"D Lane","year":"2018","unstructured":"Lane D, Matte I, Garde-Granger P, Bessette P, Piche A (2018) Ascites IL-10 promotes ovarian cancer cell migration. Cancer Microenviron 11(2\u20133):115\u2013124","journal-title":"Cancer Microenviron"},{"issue":"2","key":"3_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","volume":"367","author":"MH Mannino","year":"2015","unstructured":"Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367(2):103\u2013107","journal-title":"Cancer Lett"},{"issue":"3","key":"3_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/147323000703500302","volume":"35","author":"J Zhou","year":"2007","unstructured":"Zhou J, Ye F, Chen H, Lv W, Gan N (2007) The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35(3):290\u2013300","journal-title":"J Int Med Res"},{"issue":"2\u20133","key":"3_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","volume":"51","author":"T Sato","year":"2011","unstructured":"Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51(2\u20133):170\u2013182","journal-title":"Immunol Res"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fimmu.2011.00029","volume":"2","author":"KM Hart","year":"2011","unstructured":"Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B (2011) IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2:29","journal-title":"Front Immunol"},{"issue":"2","key":"3_CR42","first-page":"2365","volume":"17","author":"L Zhang","year":"2019","unstructured":"Zhang L, Liu W, Wang X, Wang X, Sun H (2019) Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett 17(2):2365\u20132369","journal-title":"Oncol Lett"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fonc.2015.00031","volume":"5","author":"FZ Li","year":"2015","unstructured":"Li FZ, Dhillon AS, Anderson RL, McArthur G, Ferrao PT (2015) Phenotype switching in melanoma: implications for progression and therapy. Front Oncol 5:31","journal-title":"Front Oncol"},{"issue":"5","key":"3_CR44","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.3892\/or.2017.5533","volume":"37","author":"GB Park","year":"2017","unstructured":"Park GB, Chung YH, Kim D (2017) Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells. Oncol Rep 37(5):3137\u20133145","journal-title":"Oncol Rep"},{"issue":"7","key":"3_CR45","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/labinvest.2013.69","volume":"93","author":"CY Liu","year":"2013","unstructured":"Liu CY, Xu JY, Shi XY et al (2013) M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4\/IL-10 signaling pathway. Lab Investig 93(7):844\u2013854","journal-title":"Lab Investig"},{"issue":"5","key":"3_CR46","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.bbamcr.2014.01.021","volume":"1843","author":"C Gemelli","year":"2014","unstructured":"Gemelli C, Marani TZ, Bicciato S et al (2014) MafB is a downstream target of the IL-10\/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. Biochimi Biophys Acta 1843(5):955\u2013964","journal-title":"Biochimi Biophys Acta"},{"issue":"4","key":"3_CR47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10495-016-1334-2","volume":"22","author":"Y Liu","year":"2017","unstructured":"Liu Y, Gong W, Yang ZY et al (2017) Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3\/Bcl-2 axis in ovarian cancer. Apoptosis 22(4):544\u2013557","journal-title":"Apoptosis"},{"issue":"19","key":"3_CR48","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1158\/0008-5472.CAN-07-0575","volume":"67","author":"H-W Lo","year":"2007","unstructured":"Lo H-W, Hsu S-C, Xia W et al (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67(19):9066\u20139076","journal-title":"Cancer Res"},{"issue":"6","key":"3_CR49","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","volume":"16","author":"PP Santoiemma","year":"2015","unstructured":"Santoiemma PP, Powell DJ Jr (2015) Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther 16(6):807\u2013820","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"3_CR50","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/ijms20122927","volume":"20","author":"E Ghisoni","year":"2019","unstructured":"Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G (2019) Ovarian cancer immunotherapy: turning up the heat. Int J Mol Sci 20(12):2927","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3_CR51","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899","journal-title":"Cell"},{"issue":"7161","key":"3_CR52","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449(7161):419\u2013426","journal-title":"Nature"},{"issue":"10","key":"3_CR53","doi-asserted-by":"publisher","first-page":"e47190","DOI":"10.1371\/journal.pone.0047190","volume":"7","author":"YL Chen","year":"2012","unstructured":"Chen YL, Chang MC, Chen CA, Lin HW, Cheng WF, Chien CL (2012) Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS One 7(10):e47190","journal-title":"PLoS One"},{"issue":"8","key":"3_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00262-017-1958-2","volume":"66","author":"CS Chae","year":"2017","unstructured":"Chae CS, Teran-Cabanillas E, Cubillos-Ruiz JR (2017) Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. Cancer Immunol Immunother 66(8):969\u2013977","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"3_CR55","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2217\/imt.12.100","volume":"4","author":"JL Tanyi","year":"2012","unstructured":"Tanyi JL, Chu CS (2012) Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. Immunotherapy 4(10):995\u20131009","journal-title":"Immunotherapy"},{"issue":"6","key":"3_CR56","first-page":"414","volume":"82","author":"I Wertel","year":"2011","unstructured":"Wertel I, Polak G, Tarkowski R, Kotarska M (2011) Evaluation of IL-10 and TGF-beta levels and myeloid and lymphoid dendritic cells in ovarian cancer patients. Ginekol Pol 82(6):414\u2013420","journal-title":"Ginekol Pol"},{"issue":"1","key":"3_CR57","doi-asserted-by":"publisher","first-page":"e55487","DOI":"10.1371\/journal.pone.0055487","volume":"8","author":"WH Liu","year":"2013","unstructured":"Liu WH, Liu JJ, Wu J et al (2013) Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1\/STAT3 signaling pathway. PLoS One 8(1):e55487","journal-title":"PLoS One"},{"issue":"6","key":"3_CR58","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.4049\/jimmunol.1003348","volume":"187","author":"G Posselt","year":"2011","unstructured":"Posselt G, Schwarz H, Duschl A, Horejs-Hoeck J (2011) Suppressor of cytokine signaling 2 is a feedback inhibitor of TLR-induced activation in human monocyte-derived dendritic cells. J Immunol 187(6):2875\u20132884","journal-title":"J Immunol"},{"issue":"12","key":"3_CR59","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.bcp.2010.07.040","volume":"80","author":"M Conzelmann","year":"2010","unstructured":"Conzelmann M, Wagner AH, Hildebrandt A et al (2010) IFN-gamma activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production. Biochem Pharmacol 80(12):2074\u20132086","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"3_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13048-017-0320-9","volume":"10","author":"O Sipak-Szmigiel","year":"2017","unstructured":"Sipak-Szmigiel O, Wlodarski P, Ronin-Walknowska E et al (2017) Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies. J Ovarian Res 10(1):25","journal-title":"J Ovarian Res"},{"issue":"2","key":"3_CR61","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11670-012-0130-y","volume":"24","author":"CZ Liu","year":"2012","unstructured":"Liu CZ, Zhang L, Chang XH et al (2012) Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res 24(2):130\u2013137","journal-title":"Chin J Cancer Res"},{"issue":"8","key":"3_CR62","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/mt.2011.29","volume":"19","author":"S-N Zhang","year":"2011","unstructured":"Zhang S-N, Choi I-K, Huang J-H, Yoo J-Y, Choi K-J, Yun C-O (2011) Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 19(8):1558\u20131568","journal-title":"Mol Ther"},{"issue":"3","key":"3_CR63","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3121\/cmr.3.3.166","volume":"3","author":"MA Wallet","year":"2005","unstructured":"Wallet MA, Sen P, Tisch R (2005) Immunoregulation of dendritic cells. Clin Med Res 3(3):166\u2013175","journal-title":"Clin Med Res"},{"issue":"3","key":"3_CR64","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/08820139.2017.1280051","volume":"46","author":"C Maccalli","year":"2017","unstructured":"Maccalli C, Parmiani G, Ferrone S (2017) Immunomodulating and immunoresistance properties of cancer-initiating cells: implications for the clinical success of immunotherapy. Immunol Investig 46(3):221\u2013238","journal-title":"Immunol Investig"},{"issue":"11","key":"3_CR65","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamasurg.2016.2346","volume":"151","author":"RB Batchu","year":"2016","unstructured":"Batchu RB, Gruzdyn OV, Qazi AM et al (2016) Pancreatic cancer cell lysis by cell-penetrating peptide-MAGE-A3-induced cytotoxic T lymphocytes. JAMA Surg 151(11):1086\u20131088","journal-title":"JAMA Surg"},{"key":"3_CR66","unstructured":"Batchu RB, Gruzdyn OV, Qazi A, Mahmud EM, Weaver DW, Gruber SA (2016) Pancreatic cancer-induced microenvironment inhibits dendritic cell activation via decreased nuclear localization of NF-kB. 73rd central surgical association, Montreal, Quebec, 10\u201312 Mar 2016"},{"issue":"4","key":"3_CR67","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.jamcollsurg.2015.08.384","volume":"221","author":"RB Batchu","year":"2015","unstructured":"Batchu RB, Qazi A, Gruzdyn OV et al (2015) Inhibition of epithelial ovarian cancer (EOC)-induced microenvironment can restore dendritic cell (DC) activation and migration. J Am Coll Surg 221(4):e33","journal-title":"J Am Coll Surg"},{"key":"3_CR68","unstructured":"Batchu RB, Qazi A, Gruzdyn OV et al IL-10 and TGF-b blockade reverses the inhibitory effects of pancreatic carcinoma on dendritic cell activation and migration. Paper presented at: 39th association of VA surgeons, Miami Beach, FL, 2\u20135 May 2015"},{"issue":"8","key":"3_CR69","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.vaccine.2013.12.049","volume":"32","author":"RB Batchu","year":"2014","unstructured":"Batchu RB, Gruzdyn OV, Moreno-Bost AM et al (2014) Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine 32(8):938\u2013943","journal-title":"Vaccine"},{"issue":"1","key":"3_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13193-013-0277-0","volume":"5","author":"RB Batchu","year":"2014","unstructured":"Batchu RB, Gruzdyn OV, Kung ST, Gruber SA, Weaver DW (2014) Dendritic cell based immunotherapy of cancer with cell penetrating domains. Indian J Surg Oncol 5(1):3\u20134","journal-title":"Indian J Surg Oncol"},{"issue":"5","key":"3_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jamasurg.2013.4113","volume":"149","author":"RB Batchu","year":"2014","unstructured":"Batchu RB, Gruzdyn O, Potti RB, Weaver DW, Gruber SA (2014) MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine. JAMA Surg 149(5):451\u2013457","journal-title":"JAMA Surg"},{"key":"3_CR72","doi-asserted-by":"crossref","unstructured":"Batchu RB, Gruzdyn OV, Kolli BK et al (2020) Inhibition of IL-10 in the tumor microenvironment potentiates mesothelin-chimeric antigen receptor NK-92MI-mediated killing of ovarian cancer cells. J Am Coll Surg","DOI":"10.1016\/j.jamcollsurg.2020.08.133"},{"issue":"4","key":"3_CR73","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.surg.2019.05.047","volume":"166","author":"RB Batchu","year":"2019","unstructured":"Batchu RB, Gruzdyn OV, Tavva PS et al (2019) Engraftment of mesothelin chimeric antigen receptor using a hybrid sleeping beauty\/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. Surgery 166(4):503\u2013508","journal-title":"Surgery"},{"issue":"4","key":"3_CR74","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/j.jamcollsurg.2018.08.583","volume":"227","author":"RB Batchu","year":"2018","unstructured":"Batchu RB, Gruzdyn OV, Rohondia S et al (2018) Inhibition of IL-10 augments mesothelin chimeric antigen receptor T cell activity in epithelial ovarian cancer. J Am Coll Surg 227(4):e215\u2013e216","journal-title":"J Am Coll Surg"},{"issue":"3","key":"3_CR75","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.surg.2017.10.056","volume":"163","author":"RB Batchu","year":"2018","unstructured":"Batchu RB, Gruzdyn OV, Mahmud EM et al (2018) Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Surgery 163(3):627\u2013632","journal-title":"Surgery"},{"issue":"4","key":"3_CR76","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.jamcollsurg.2017.07.645","volume":"225","author":"O Gruzdyn","year":"2017","unstructured":"Gruzdyn O, Batchu RB, Mahmud EM et al (2017) Mesothelin chimeric antigen receptor (CAR)-mediated therapy for ovarian cancer. J Am Coll Surg 225(4):e47","journal-title":"J Am Coll Surg"},{"issue":"1","key":"3_CR77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-007-0347-7","volume":"57","author":"TM Carr","year":"2008","unstructured":"Carr TM, Adair SJ, Fink MJ, Hogan KT (2008) Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol Immunother 57(1):31\u201342","journal-title":"Cancer Immunol Immunother"},{"key":"3_CR78","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1471-2407-10-163","volume":"10","author":"S Zhang","year":"2010","unstructured":"Zhang S, Zhou X, Yu H, Yu Y (2010) Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 10:163","journal-title":"BMC Cancer"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biomaterials.2018.12.019","volume":"195","author":"AL Coolen","year":"2019","unstructured":"Coolen AL, Lacroix C, Mercier-Gouy P et al (2019) Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials 195:23\u201337","journal-title":"Biomaterials"},{"issue":"1","key":"3_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4110\/in.2016.16.1.33","volume":"16","author":"S Lim","year":"2016","unstructured":"Lim S, Koo JH, Choi JM (2016) Use of cell-penetrating peptides in dendritic cell-based vaccination. Immune Netw 16(1):33\u201343","journal-title":"Immune Netw"},{"issue":"2","key":"3_CR81","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jconrel.2006.10.031","volume":"117","author":"A Chauhan","year":"2007","unstructured":"Chauhan A, Tikoo A, Kapur AK, Singh M (2007) The taming of the cell penetrating domain of the HIV tat: myths and realities. J Control Release 117(2):148\u2013162","journal-title":"J Control Release"},{"issue":"21","key":"3_CR82","doi-asserted-by":"publisher","first-page":"10041","DOI":"10.1158\/0008-5472.CAN-05-1383","volume":"65","author":"RB Batchu","year":"2005","unstructured":"Batchu RB, Moreno AM, Szmania SM et al (2005) Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res 65(21):10041\u201310049","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"3_CR83","doi-asserted-by":"publisher","first-page":"B61","DOI":"10.1016\/j.vaccine.2007.06.038","volume":"25","author":"VG Brichard","year":"2007","unstructured":"Brichard VG, Lejeune D (2007) GSK\u2019s antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 25(Suppl 2):B61\u2013B71","journal-title":"Vaccine"},{"issue":"22","key":"3_CR84","first-page":"6272","volume":"60","author":"ES Schultz","year":"2000","unstructured":"Schultz ES, Lethe B, Cambiaso CL et al (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 60(22):6272\u20136275","journal-title":"Cancer Res"},{"issue":"4","key":"3_CR85","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583\u2013593","journal-title":"Clin Microbiol Rev"},{"issue":"19","key":"3_CR86","doi-asserted-by":"publisher","first-page":"9493","DOI":"10.1128\/JVI.75.19.9493-9501.2001","volume":"75","author":"S Ponnazhagan","year":"2001","unstructured":"Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR (2001) Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 75(19):9493\u20139501","journal-title":"J Virol"},{"issue":"3","key":"3_CR87","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4161\/cbt.4.3.1499","volume":"4","author":"N Korokhov","year":"2005","unstructured":"Korokhov N, de Gruijl TD, Aldrich WA et al (2005) High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther 4(3):289\u2013294","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"3_CR88","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1089\/hum.2010.087","volume":"21","author":"JE Ussher","year":"2010","unstructured":"Ussher JE, Taylor JA (2010) Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6. Hum Gene Ther 21(12):1675\u20131686","journal-title":"Hum Gene Ther"},{"key":"3_CR89","doi-asserted-by":"crossref","unstructured":"Vazquez J, Chavarria M, Lopez GE et al (2020) Identification of unique clusters of T, dendritic and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients. Am J Reprod Immunol 84(3):e13284","DOI":"10.1111\/aji.13284"},{"issue":"4","key":"3_CR90","doi-asserted-by":"publisher","first-page":"e0175712","DOI":"10.1371\/journal.pone.0175712","volume":"12","author":"E Brencicova","year":"2017","unstructured":"Brencicova E, Jagger AL, Evans HG et al (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS One 12(4):e0175712","journal-title":"PLoS One"},{"issue":"3","key":"3_CR91","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/CJI.0000000000000030","volume":"37","author":"HE Goyne","year":"2014","unstructured":"Goyne HE, Stone PJ, Burnett AF, Cannon MJ (2014) Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indole amine 2,3-dioxygenase. J Immunother 37(3):163\u2013169","journal-title":"J Immunother"},{"issue":"5","key":"3_CR92","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/CJI.0b013e3181a59fa9","volume":"32","author":"C Scholz","year":"2009","unstructured":"Scholz C, Rampf E, Toth B et al (2009) Ovarian cancer-derived glycodelin impairs in vitro dendritic cell maturation. J Immunother 32(5):492\u2013497","journal-title":"J Immunother"},{"issue":"4","key":"3_CR93","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s002800100331","volume":"48","author":"E Zavadova","year":"2001","unstructured":"Zavadova E, Savary CA, Templin S, Verschraegen CF, Freedman RS (2001) Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother Pharmacol 48(4):289\u2013296","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3_CR94","first-page":"156","volume":"24","author":"B Melichar","year":"2001","unstructured":"Melichar B, Touskova M, Tosner J, Kopecky O (2001) The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie 24(2):156\u2013160","journal-title":"Onkologie"},{"issue":"2","key":"3_CR95","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3892\/ol.2015.4044","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Yi J, Chen X, Zhang Y, Xu M, Yang Z (2016) The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-beta and IL-10. Oncol Lett 11(2):1527\u20131530","journal-title":"Oncol Lett"},{"issue":"7","key":"3_CR96","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11605-013-2194-5","volume":"17","author":"X Huang","year":"2013","unstructured":"Huang X, Zou Y, Lian L et al (2013) Changes of T cells and cytokines TGF-beta1 and IL-10 in mice during liver metastasis of colon carcinoma: implications for liver anti-tumor immunity. J Gastrointest Surg 17(7):1283\u20131291","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"3_CR97","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/01926230490505059","volume":"32","author":"AL Spinardi-Barbisan","year":"2004","unstructured":"Spinardi-Barbisan AL, Barbisan LF, de Camargo JL, Rodrigues MA (2004) Infiltrating CD8+ T lymphocytes, natural killer cells, and expression of IL-10 and TGF-beta1 in chemically induced neoplasms in male Wistar rats. Toxicol Pathol 32(5):548\u2013557","journal-title":"Toxicol Pathol"},{"issue":"8","key":"3_CR98","first-page":"2209","volume":"60","author":"M Hirao","year":"2000","unstructured":"Hirao M, Onai N, Hiroishi K et al (2000) CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60(8):2209\u20132217","journal-title":"Cancer Res"},{"issue":"1","key":"3_CR99","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/1078-0432.CCR-16-0081","volume":"23","author":"A Montfort","year":"2017","unstructured":"Montfort A, Pearce O, Maniati E et al (2017) A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res 23(1):250\u2013262","journal-title":"Clin Cancer Res"},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1600-065X.2008.00614.x","volume":"222","author":"BH Nelson","year":"2008","unstructured":"Nelson BH (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222:101\u2013116","journal-title":"Immunol Rev"},{"issue":"1","key":"3_CR101","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore KW, de Waal MR, Coffman RL, O\u2019Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19(1):683\u2013765","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"3_CR102","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clim.2011.11.011","volume":"142","author":"MA Boks","year":"2012","unstructured":"Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, ten Brinke A (2012) IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction\u2014a comparative study of human clinical-applicable DC. Clin Immunol 142(3):332\u2013342","journal-title":"Clin Immunol"},{"issue":"8","key":"3_CR103","first-page":"1860","volume":"63","author":"JJ Kobie","year":"2003","unstructured":"Kobie JJ, Wu RS, Kurt RA et al (2003) Transforming growth factor \u03b2 inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63(8):1860\u20131864","journal-title":"Cancer Res"},{"issue":"1","key":"3_CR104","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpain.2012.09.015","volume":"14","author":"JT Liou","year":"2013","unstructured":"Liou JT, Mao CC, Ching-Wah Sum D et al (2013) Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model. J Pain 14(1):24\u201335","journal-title":"J Pain"},{"key":"3_CR105","unstructured":"Prazeres PHDM, Leonel C, Walison NS et al (2020) Ablation of sensory nerves favours melanoma progression. J Cell Mol Med 24(17):9574\u20139589"},{"issue":"3","key":"3_CR106","first-page":"631","volume":"30","author":"HR Turnquist","year":"2007","unstructured":"Turnquist HR, Lin X, Ashour AE et al (2007) CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncol 30(3):631\u2013639","journal-title":"Int J Oncol"},{"issue":"6","key":"3_CR107","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1080\/21645515.2018.1431598","volume":"14","author":"C Thepmalee","year":"2018","unstructured":"Thepmalee C, Panya A, Junking M, Chieochansin T, Yenchitsomanus PT (2018) Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. Hum Vaccin Immunother 14(6):1423\u20131431","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"3_CR108","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/CJI.0000000000000212","volume":"41","author":"JT Gordy","year":"2018","unstructured":"Gordy JT, Luo K, Francica B, Drake C, Markham RB (2018) Anti-IL-10-mediated enhancement of antitumor efficacy of a dendritic cell-targeting MIP3\u03b1-gp100 vaccine in the B16F10 mouse melanoma model is dependent on type I interferons. J Immunother 41(4):181\u2013189","journal-title":"J Immunother"},{"issue":"4","key":"3_CR109","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/ijc.32151","volume":"145","author":"L Yang","year":"2019","unstructured":"Yang L, Dong Y, Li Y et al (2019) IL-10 derived from M2 macrophage promotes cancer stemness via JAK1\/STAT1\/NF-kappaB\/Notch1 pathway in non-small cell lung cancer. Int J Cancer 145(4):1099\u20131110","journal-title":"Int J Cancer"},{"key":"3_CR110","unstructured":"Harrington BS, Annunziata CM (2019) NF-kappaB signaling in ovarian cancer. Cancers (Basel) 11(8):1182"},{"issue":"10","key":"3_CR111","doi-asserted-by":"publisher","first-page":"e0164189","DOI":"10.1371\/journal.pone.0164189","volume":"11","author":"RM Ignacio","year":"2016","unstructured":"Ignacio RM, Kabir SM, Lee ES, Adunyah SE, Son DS (2016) NF-kappaB-mediated CCL20 reigns dominantly in CXCR2-driven ovarian Cancer progression. PLoS One 11(10):e0164189","journal-title":"PLoS One"},{"issue":"3","key":"3_CR112","doi-asserted-by":"publisher","first-page":"e1758","DOI":"10.1371\/journal.pone.0001758","volume":"3","author":"N Yang","year":"2008","unstructured":"Yang N, Huang J, Greshock J et al (2008) Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One 3(3):e1758","journal-title":"PLoS One"}],"container-title":["Advances in Experimental Medicine and Biology","Tumor Microenvironment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-55617-4_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:21:17Z","timestamp":1724455277000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-55617-4_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030556167","9783030556174"],"references-count":112,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-55617-4_3","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"10 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}